hospira inc (HSP) Key Developments
Hospira, Inc. Announces Availability of INFLECTRA™ (Infliximab) in Canada
Mar 30 15
Hospira Inc. announced the availability of INFLECTRA™ (infliximab) in Canada. Approved by Health Canada, INFLECTRA is available to healthcare practitioners for the treatment of patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA) and plaque psoriasis. INFLECTRA is biosimilar to the reference product REMICADE® (infliximab).
Clinigen Group Plc Extends Foscavir U.S Distribution Contract with Hospira, Inc
Mar 11 15
Clinigen Group Plc announced the extension and renegotiation of the exclusive license and distribution agreement with Hospira Inc. for its anti-viral product Foscavir (foscarnet sodium) in the U.S. This is expected to be beneficial to both parties. The original distribution agreement with Hospira established in July 2011 was due to expire in May 2017. The new agreement is for five years extending the term to 31 December 2019.
Hospira Launches Remicade Biosimilar Inflectra in Additional European Countries
Feb 24 15
Hospira announced that it is launching its Remicade biosimilar Inflectra in at least 10 new European markets, nearly doubling the product's presence on the continent. Inflectra (infliximab) is the first biosimilar monoclonal antibody to be marketed in Europe, will soon be available in Austria, Sweden, Denmark, France, Germany, Greece, Italy, Luxembourg, the Netherlands and Spain. Inflectra mimics Janssen's Remicade (infliximab), which treats inflammatory diseases such as psoriatic and rheumatoid arthritis, ankylosing spondylitis, adult and pediatric Crohn's disease, plaque psoriasis and ulcerative colitis.
Hospira Posts Interim Results from Patient Registry for Biosimilar Inflectra in IBD Treatment
Feb 23 15
Hospira (US) presented interim results from a patient registry study at the European Crohn's and Colitis Organisation's conference on inflammatory bowel diseases (IBDs) in Barcelona, Spain, on 19 February. The study looked at the firm's biosimilar version of Remicade (infliximab; Johnson & Johnson; J&J, US), Inflectra. The results from the ongoing independent, prospective study conducted in 90 patients across Hungary demonstrated comparable efficacy between Inflectra and Remicade for inducing and maintaining remission of Crohn's disease (CD) and ulcerative colitis (UC). So far, the patients who were treated with Inflectra for either CD (57) or UC (33) demonstrated reductions in disease activity at two and six weeks post treatment. Levels of C-reactive protein, a marker for inflammation, also declined in UC patients. With regards to safety and tolerability, Hospira reports that 4 of the 90 patients had an allergic reaction to Inflectra. The four patients have previously received anti- tumour necrosis factor treatment. The registry trial will continue to enrol patients and will follow CD patients for 108 weeks and UC patients for 54 weeks in order to assess the safety, adherence, long-term outcomes, and the cost of treatment with Inflectra.
Shareholders Foundation Announces Investor Lawsuit Against Acquisition of Hospira, Inc
Feb 17 15
The Shareholders Foundation Inc. announced that an investor, who currently holds shares of Hospira Inc., filed a lawsuit in effort to stop the proposed takeover of Hospira Inc. by Pfizer for $90 per share. The plaintiff alleges that the defendants breached their fiduciary duties owed to stockholders by agreeing to sell Hospira Inc. too cheaply via an unfair process to Pfizer Inc. On February 5, 2015, Pfizer Inc. and Hospira Inc. announced that they have entered into a merger agreement under which Pfizer will acquire Hospira for $90 a share in cash for a total enterprise value of approximately $17 billion. However, the plaintiff claims that the $90-offer is too low and undervalues Hospira Inc. In addition, the plaintiff claims that the process is also unfair to stockholders.